• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Liraglutide in the treatment of obesity
【24h】

Liraglutide in the treatment of obesity

机译：利拉鲁肽治疗肥胖症

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Obesity is a global epidemic with important healthcare and financial implications. Most current antiobesity pharmacological therapies are unsatisfactory due to undesirable side effects. Many drugs have been withdrawn due to safety concerns. Maintaining weight loss remains the Achilles' heel of antiobesity therapy.Areas covered: This is an overview of the use of liraglutide for obesity treatment. Clinical efficacy on weight, cardiovascular parameters, as well as safety and tolerability issues are discussed.Expert opinion: Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, which has a protracted pharmacokinetic profile compared to native GLP-1 while maintaining its biological activity. It induces weight loss by reducing appetite and energy intake. It stimulates insulin release and decreases glucagon secretion in response to hyperglycaemia. Treatment with liraglutide, in addition with diet and exercise, induces sustained mean weight loss of 7.6 kg at 2 years (weight loss induced by orlistat = 5.7 kg, phentermine/topiramate controlled release 15/92 = 10.9 kg). It reduces blood pressure and improves glycaemic control, which has clinically relevant significance on reducing obesity-related morbidity and mortality. Liraglutide is reasonably well tolerated with gastrointestinal side effects being most commonly encountered. Novo Nordisk filed for regulatory approval of liraglutide 3.0 mg for obesity treatment in December 2013.
机译：简介：肥胖症是一种全球流行病，具有重要的医疗保健和财务影响。由于不希望的副作用，大多数当前的抗肥胖药理学疗法不能令人满意。出于安全考虑，已经撤回了许多药物。维持体重减轻仍然是减肥疗法的致命弱点。覆盖范围：这是利拉鲁肽用于肥胖治疗的概述。讨论了有关体重，心血管参数以及安全性和耐受性问题的临床疗效专家意见：利拉鲁肽是一种胰高血糖素样肽1（GLP-1）受体激动剂，与天然GLP-1相比具有更长的药代动力学特性保持其生物活性。它通过减少食欲和能量摄入而引起体重减轻。响应高血糖症，它刺激胰岛素释放并减少胰高血糖素分泌。除饮食和运动外，利拉鲁肽治疗还可导致2年持续平均体重减轻7.6千克（奥利司他引起的体重减轻= 5.7千克，芬特明/托吡酯控释15/92 = 10.9千克）。它可以降低血压并改善血糖控制，这在降低肥胖相关的发病率和死亡率方面具有临床意义。利拉鲁肽具有相当好的耐受性，最常见的是胃肠道副作用。 2013年12月，诺和诺德（Novo Nordisk）申请了利拉鲁肽3.0毫克用于肥胖症治疗的监管批准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号